CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD47 单克隆抗体增强抗 HER2 嵌合抗原受体巨噬细胞对卵巢癌的抑制作用

CD47 monoclonal antibody enhances the inhibitory effect of anti-HER2 chimeric antigen receptor macrophages on ovarian cancer.

CCL19 武装的溶瘤腺病毒与表达 CCR7 的 CAR-T 细胞协同抑制卵巢肿瘤生长

CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth.

GPR183 通过涉及氧固醇 7α, 25-OHC 的正反馈环路增强 CAR-T 细胞浸润与抗肿瘤免疫

GPR183 potentiates CAR-T cell infiltration and antitumor immunity through a positive feedback loop involving the oxysterol 7α,25-OHC.

本研究首次揭示，GPR183 介导的正反馈环路是调控 T 细胞肿瘤浸润的关键新机制。通过基因工程增强 GPR183 表达是一种有前景的策略，可显著提高 CAR-T 细胞的迁移能力和抗肿瘤功能，从而为克服当前实体瘤治疗的局限性提供了新的治疗靶点和理论基础。

卵巢癌 CAR-T 细胞治疗进展：当前策略与未来方向

Advancements in CAR-T Cell Therapy for Ovarian Cancer: Current Strategies and Future Directions.

阻断共抑制受体免疫检查点蛋白 TIM3/CD366 增强实体瘤 CAR-T 疗法的抗肿瘤活性：以卵巢癌为例

Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian